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Incorporation of the glycolipid trehalose 6,6V-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound
dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong
antibody response, desirable for a high number of disease targets. We have used differential scanning calorimetry (DSC) to investigate the effect of
TDB on the gel-fluid phase transition of DDA liposomes and to demonstrate that TDB is incorporated into DDA liposome bilayers. Transmission
Electron Microscopy (TEM) and cryo-TEM confirmed that liposomes were formed when a lipid film of DDA containing small amounts of TDB
was hydrated in an aqueous buffer solution at physiological pH. Furthermore, time development of particle size and zeta potential of DDA
liposomes incorporating TDB during storage at 4 -C and 25 -C, indicates that TDB effectively stabilizes the DDA liposomes. Immunization of
mice with the mycobacterial fusion protein Ag85B–ESAT-6 in DDA–TDB liposomes induced a strong, specific Th1 type immune response
characterized by substantial production of the interferon-g cytokine and high levels of IgG2b isotype antibodies. The lymphocyte subset releasing
the interferon-g was identified as CD4 T cells.
D 2005 Published by Elsevier B.V.Keywords: Adjuvant; Immunomodulator; Liposome; Trehalose 6,6V-dibehenate; Dimethyldioctadecylammonium1. Introduction
Subunit vaccines with improved safety profiles based on
well-defined recombinant proteins or peptides are poorly
immunogenic when administered alone. Adjuvants are there-
fore needed in the vaccine formulation to induce an adequate
immune response. Selecting the appropriate adjuvant to
specific antigenic components will not only enhance the level
of immune response but will also determine the type of
immune response induced [1]. In contrast to the substantial
progress made in techniques to identify and produce antigens,
the most widely used adjuvants are still aluminum based0005-2736/$ - see front matter D 2005 Published by Elsevier B.V.
doi:10.1016/j.bbamem.2005.10.011
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E-mail address: eag@ssi.dk (E.M. Agger).compounds (generically called alum); although a squalene
based oil emulsion (MF59) and virosomes for use in influenza
vaccines are approved for human use in Europe [1]. Alum
generally promotes weak humoral Th2 type immune responses
to protein subunits, and elicits insufficient cell-mediated Th1
immune responses [1,2]. In particular, the failure of alum to
stimulate a cell mediated Th1 immune response, required for
protective immunity against many cancers and infectious
diseases has led to the search for more potent vaccine adjuvants
that not only enhance the level of immune activation but also
selectively induce cell-mediated immune responses.
The quaternary ammonium compound, dimethyldioctade-
cylammonium (DDA), has previously been reported as an
effective adjuvant for eliciting cell-mediated and humoral
responses. DDA was discovered as an adjuvant by Gall inta 1718 (2005) 22 – 31
http://www
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number of different viral and bacterial antigens in different
animal species [4–9]. DDA is a synthetic amphiphilic lipid
compound comprising a hydrophilic positively charged
dimethylammonium head–group attached to two hydrophobic
18-carbon alkyl chains (tail). In an aqueous environment, DDA
self-assemble into closed vesicular bilayers similar to lipo-
somes made from natural phospholipids [10–13]. In general,
vesicle size, polydispersity, thermotropic phase behavior,
surface potential and physical stability of the DDA liposomes
depend on the concentration of the amphiphile, preparation
method and solvent conditions, e.g., buffer substance, pH and
salt concentration [11,14–16]. Unfortunately, DDA liposomes
are physically unstable. Small amounts of salt result in
instantaneous aggregation, possibly due to reduced long range
electrostatic repulsion between the positively charged DDA
liposomes. Salt-induced aggregation is to some extent revers-
ible as removing the salts restores the liposome dispersion
[11,16–18]. However, even in pure water DDA vesicles
aggregate over time, indicating that electrostatic repulsion
forces between the cationic liposomes are insufficient to
stabilize the vesicles [19].
In this paper, we demonstrate a unique way to increase both
stability and adjuvant efficacy of DDA liposomes by incorpo-
rating trehalose 6,6V-dibehenate (TDB), a glycolipid comprising
a 6,6V-diester of a,aV-trehalose with two long 22-carbon acyl
chains (behenic acids), into the DDA liposome bilayers. TDB is
a synthetic analogue of trehalose 6,6V-dimycolate (TDM) often
referred to as cord factor, which is an immunostimulatory
component of the mycobacterial cell wall [20,21]. However,
compared to TDM, the TDB has shorter fatty acid chains which
have been associated with lower toxicity [20,22]. As a model
antigen, we selected the Ag85B–ESAT-6 fusion protein [8]
which is a promising tuberculosis vaccine antigen. Administra-
tion of Ag85B–ESAT-6 in the DDA–TDB liposomes induces a
very substantial CMI as well as humoral response with a strong
Th1 bias, as demonstrated by the high titers of IgG2b and high
levels of IFN-g release from the T cells primed by the vaccine.
2. Materials and methods
2.1. Materials
Dimethyldioctadecylammonium (DDA) bromide and a,aV-trehalose 6,6V-
dibehenate (TDB) were obtained from Avanti Polar Lipids (Alabaster, AL). The
purity of the compounds was >99% by HPLC. Methanol (extra pure),
chloroform (extra pure) and 1 M hydrochloric acid, used to adjust pH in the
Tris-buffer, were purchased from Merck (Darmstadt, Germany). Tris base
(99%) and Sephadex G-75 were obtained from Sigma-Aldrich (St. Louis, MO).
Purified water of Milli Q quality was used to prepare all samples. Non-his-
tagged protein Ag85B–ESAT-6 was produced in Escherichia Coli as described
previously for the His-tagged version [8], purified by column chromatography
and dissolved in 10 mM Tris-buffer, pH 7.4, at a concentration of 0.5 mg/ml.
Alhydrogel (Alum) was purchased at Brenntag Biosector (Frederikssund,
Denmark). For radiolabelling of the antigen, Iodo-genR pre-coated iodination
tubes from Pierce Biotechnology (Rockford, IL) were used and 125I (NaI in
NaOH solution) was purchased from Amersham Biosciences (Amersham, UK).
Round-bottomed 96-well microtiter plates were obtained from Nunc
(Roskilde, Denmark). RPMI 1640 medium was obtained from Gibco
(Invitrogen, Carlsbad, CA), 2-mercaptoethanol from Sigma-Aldrich, gluta-mine (Gibco), penicillin–streptomycin (Gibco) HEPES (Gibco), and 10%
fetal calf serum from Biochrom AG (Berlin, Germany). ConA was obtained
from Sigma-Aldrich.
Plates for enzyme linked immunosorbent assay (ELISA) were from Nunc
and HRP-conjugated secondary antibodies (rabbit anti-mouse IgG1 and IgG2b,
was obtained from Zymed (San Francisco, CA). TMB substrate was
manufactured by Kem-En-Tec (Copenhagen, Denmark).
2.2. Preparation of adjuvant liposomes
DDA liposomes in the presence or absence of TDB were prepared by two
different methods:
2.2.1. Lipid film hydration method
Unilamellar DDA liposomes containing increasing concentrations of TDB
were prepared by the film method. Weighed amounts of DDA and TDB were
dissolved in chloroform/methanol (9:1, by volume) and the organic solvent was
removed using a gentle stream of N2 forming a thin lipid film at the bottom of
the test tube. The lipid film was dried over night under low pressure to remove
trace amounts of the organic solvent. Unilamellar vesicles were formed by
simply hydrating the lipid film in 10 mM Tris-buffer at pH 7.4 [15,23,24]. The
lipid film was hydrated for 20 min at a temperature 10 -C above the main phase
transition of DDA (Tm 47 -C) [15,25] to ensure complete hydration.
The final DDA concentration was fixed at 1.25 mg/ml (2.0 mM) whereas
the amount of TDB varied between 0 and 0.5 mg/ml (0 and 0.5 mM). Four
different formulations were prepared containing the following amounts of
TDB: 0, 0.125, 0.25, and 0.5 mg/ml (0, 0.125, 0.25, and 0.5 mM). The mole
fraction of TDB corresponds to 0, 6.4, 11, and 20 mol%. DDA and TDB
concentrations were determined by HPLC using a 5 Am diol column, a mobile
phase composed of MeOH/CHCl3/H2O (75:20:5, v/v/v), and an evaporative
light scattering detector. Ag85B–ESAT-6 was added to the preformed
liposomes at a fixed concentration of 0.01 mg/ml.
2.2.2. Aqueous heat method
For comparison DDA adjuvant liposomes were also prepared as described
previously [6]. Briefly, DDAwas mixed into 10 mM Tris-buffer at pH 7.4 to a
concentration of 1.25 mg/ml, heated to 80 -C for 20 min with intermittent
shaking, and then cooled to room temperature. Where appropriate, 0.25 mg/ml
of TDB (250 Al of a 1 mg/ml solution in 0.2% triethylamine) was then added,
and the resulting solution was vortexed briefly. The Ag85B–ESAT-6 was
finally added at a concentration of 0.01 mg/ml.
2.3. Dynamic light scattering: determination of liposome size and zeta
potential
The z-average diameter of DDA liposomes containing increasing concen-
trations of TDB was determined by dynamic light scattering using the photon
correlation spectroscopy (PCS) technique. The measurements were performed
at 25 -C using either a ZetaSizer 4 (Malvern Instruments, Worcestershire, UK)
equipped with a He-Ne gas laser (k =0.633 Am) or a ZetaPlus (Brookhaven
Instrument Corporation, USA). Brookhaven or Malvern PCS software (v 1.52),
depending on the system, was used for data acquisition and analysis.
Polystyrene size standards 220T6 nm (Duke scientific corp., Duke, NC) was
used to verify the performance of the instrument. For viscosity and refractive
index, the values of pure water were used (1.0). The samples were diluted with
10 mM Tris-buffer at pH 7.4 to achieve the optimal vesicle concentration.
Surface charge on the vesicles was measured indirectly via analysis of zeta
potential at 25 -C using a ZetaPlus instrument (Brookhaven Instrument
Corporation, USA) in a 1/10 solution of 10 mM Tris-buffer.
2.4. Transmission electron microscopy (TEM)
Morphological analysis was carried out by TEM using a JEOL 1200EX
TEM fitted with a LaB6 filament, with an operating voltage from 40 to 120 kV.
A small drop of sample (10 Al) was placed on a polymer filmed copper grid and
allowed to stand for 2 min. The excess sample was removed using a filter paper,
followed by addition of 10 Al of uranyl acetate. The grid was then allowed to
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film which was viewed at 70 kV.
2.5. Cryo-TEM
Further morphological analysis was carried out by Cryo-TEM using a
Philips CM120 BioTWIN transmission electron microscope. Samples for cryo-
TEM were prepared under controlled temperature and humidity conditions
within a controlled environmental verification system (CEVS). A small drop (5
Al) of sample was deposited on a Pelco Lacey carbon filmed grid. After
carefully spreading of the drop, excess liquid was removed with a filter paper,
forming thin (10–500 nm) sample films extending over the approx. 5 Am large
holes in the polymer film. Then, the sample was immediately plunged into
liquid ethane, held at 180 -C. The vitrified sample was then transferred in
liquid nitrogen to an Oxford CT3500 cryo holder connected to the electron
microscope. The sample temperature was kept below 180 -C. All observa-
tions were made in the bright field mode and an acceleration voltage of 120 kV.
Digital pictures were taken with a Gatan Imaging Filter 100 CCD camera.
2.6. 125I radiolabelling of Ag85B–ESAT-6
Radiolabelling of Ag85B–ESAT-6 was performed using the Iodo-genR
pre-coated iodination tubes (Pierce Biotechnology, Rockford, IL). Briefly,
Ag85B–ESAT-6 was diluted with 50 Al Tris-buffer (25 mM, pH 8) and added
to the pre-coated iodination tube. A pre-determined activity of 125I (3.7 MBq)
was then diluted up to 30 Al with 25 mM Tris-buffer and added to the iodination
tube. This mixture was then left for 15 min, with intermittent shaking, to
facilitate radiolabelling of Ag85B–ESAT-6.
Removal of the unlabelled Ag85B–ESAT-6 was performed by Sephadex G-
75 gel column separation. In order tomake the column, SephadexG-75 (1%,w/v)
was first soaked in double distilled water at 90 -C for 1 h, with stirring. The
swollen gel was then packed into a 5 ml column and equilibrated with the 25 mM
Tris-buffer.
Prior to separation, the reaction mixture from the iodination tube was
further diluted with the Tris-buffer, and then passed through the column with 25
mM Tris-buffer as mobile phase. Aliquots of the eluted solution (0.5 ml) were
collected and measured for gamma radiation using a Cobrai CPM Auto-
GammaR counter (Packard Instruments Company inc., IL, USA) and also for
UV absorbance at 280 nm, so as to confirm the presence of radiolabelled
Ag85B–ESAT-6. The appropriate aliquots were then pooled and stored at 20
-C until required for further use.
2.7. Adsorption of antigen to adjuvant liposomes
The degree of adsorption of Ag85B–ESAT-6 to the liposomes was
determined by 125I radiation. Radiolabelled Ag85B–ESAT-6 was added to
liposomes prepared as described above, mixed, and then allowed to stand for 10
min at ambient conditions. The formulation was then pelleted by ultracentrifu-
gation (100,000g for 1 h), resuspended in the original volume of 10 mM Tris-
buffer, and then measured for gamma radiation. Adsorption of Ag85B–ESAT-6
was determined on the basis of 125I radioactivity recovered in the suspended
pellets. At regular time intervals, a similar procedure was adopted to determine
Ag85B–ESAT-6 retention under different storage conditions (4 -C and 25 -C).
2.8. Immunization of mice
Female C57BL/6j mice, 8 to 12 weeks old, were obtained from Bomholt-
gaard (Ry, Denmark) and Harlan Scandinavia (Allerød, Denmark), respectively.
The vaccines were prepared by simply mixing preformed DDA liposome
dispersions incorporating 0, 6.4, 11 or 20 mol% TDB, respectively, with the
Ag85B–ESAT-6 stock solution to the final Ag85B–ESAT-6 concentration of
0.01 mg/ml (2 Ag in each vaccine dose). The amount of DDA and TDB in each
dose was 250 Ag and 25, 50 or 100 Ag, respectively. In vaccines with alum (500
Ag in each dose), the antigen was added immediately before immunization.
Mice were immunized subcutaneously (s.c.) with the vaccines (0.2 ml/dose)
at the base of the tails three times with a 2 weeks interval between each
immunization.2.9. Lymphocyte cultures
Blood samples were drawn from mice (n =6) 7 days after the last
immunization by periorbital puncture and the blood lymphocytes were purified
using LympholyteR-Mammal (Cedarlane, Canada) according to the manufac-
turer’s instructions. After recovery of the lymphocytes, the cells were washed
twice in RPMI and cell cultures established as previously described [26]. In brief,
cultures were performed in triplicate in round-bottomed microtiter wells (Nunc,
Denmark) containing 2105 cells in a volume of 200 Al RPMI supplemented
with 5105 M 2-mercaptoethanol, 1 mM glutamine, 1% penicillin –
streptomycin, 1% HEPES and 10% fetal calf serum (all Gibco Invitrogen,
Carlsbad, CA). Ag85B–ESAT-6 for re-stimulation was used in a concentration
of 5 Ag/ml. Wells containing medium only or 5 Ag/ml of ConAwere included in
all experiments as negative and positive controls, respectively. Furthermore, 5
Ag/ml of tetanus toxoid (SSI, Denmark) and 5 Ag/ml of merozoite surface protein
1 (a generous gift by Dr. M. Theisen) was used as negative controls.
Splenocyte cultures (n =3) were obtained by passage of spleens through a
metal mesh followed by two washing procedures using RPMI. To evaluate the
responding subset of lymphocytes, the T cell receptor were blocked by adding
monoclonal antibodies against CD4 and CD8 into the cultures 30 min before
adding the splenocyte cultures. All dilutions of antibodies were based on
previous titrations. Splenocyte cultures were grown as described for blood
lymphocytes above.
Culture supernatants were harvested from parallel cultures after 72 h of
incubation in the presence of antigen, and the amounts of IFN-g and IL-5 were
determined by ELISA as previously described [27,28].
2.10. Determination of antibody titres
Antibody titres were determined by ELISA as previously described [28].
Briefly, plates for enzyme linked immunosorbent assay (ELISA) were coated
with Ag85B–ESAT-6 (0.05 Ag /well) in PBS, and individual mouse sera from
four mice per group were analyzed in duplicate in 5-fold dilutions. HRP-
conjugated secondary antibodies (rabbit anti-mouse IgG1 and IgG2a, Zymed,
USA) diluted 1/2000 in PBS containing 1% BSA were added, and Ag85B–
ESAT-6 specific antibodies were detected by TMB substrate as described by the
manufacturer. Antibody titres were then defined as the serum dilution which
gives an absorbance value of 1.00 in the parallel portion of the curves as
previously described [29].
3. Results and discussion
3.1. Dynamic light scattering: particle size and zeta potential
In an aqueous environment, DDA self-assemble into
liposomes that have been used as an adjuvant for various
vaccines [4,6–8]. The physico-chemical characteristics of
DDA and DDA–TDB vesicles prepared by either the lipid
film hydration method or the aqueous hydration method were
studied. Results in Table 1 demonstrate that liposomes prepared
by lipid hydration were significantly smaller than liposomes of
the same composition prepared by the aqueous heat method
(400–500nm vs. 800–1300nm, respectively; Table 1). Further,
while supplementation of DDA liposomes with TDB resulted
in no significant difference in vesicle size when prepared by the
lipid hydration method, the opposite was apparent when
liposomes were prepared by the aqueous heat method, with
DDA–TDB vesicles being larger than their DDA counter-parts
(Table 1), suggesting that potentially the TDB is less
effectively incorporated/packaged within the lipid membranes
when the latter method was adopted.
The zeta potential of liposomes can both directly influence
liposome suspension stabilities and indirectly reflect vesicle
Fig. 1. (A) Time development of average particle size of DDA liposomes
containing 0 mol% (–0– ), 6 mol% (–r– ), 11 mol% (–j– ) and 20 mol%
(–˝– ) TDB stored at 4 -C. The liposomes were dispersed in 10 mM Tris
buffer adjusted to pH 7.4. A significant increase is observed for DDA
liposomes without TDB after 14 days. (B) represents average particle of DDA
(–0– ) and DDA/TDB (11 mol%) (–*– ) stored at 25 -C for up to 28 days.
Table 1
Vesicle size and zeta potential of DDA liposomes prepared from DDAwith and
without TDB (11 mol%) by either the aqueous heat or lipid hydration method
Formulation Aqueous heat method Lipid hydration method
Size (nm) ZP (mV) Size (nm) ZP (mV)
DDA 846T130 52T2.6 488T124 46T1.6
DDA+H1 929T113 47T2.6 421T26 52T3.1
DDA–TDB 1281T134 47T0.6 416T40 48T5.1
DDA–TDB+H1 1256T150 44T0.3 486T110 60T4.7
In both cases, the liposomes were dispersed in 10 mM Tris buffer with pH 7.4.
The effect of Ag85B–ESAT-6 (H1) adsorption on vesicle size and zeta
potential was measured by adding H1 (0.01 mg/ml) to the liposomes. Vesicle
size and zeta potential (ZP) was measured using a Brookhaven ZetaPlus with
zeta potential being measured in 1 mM Tris buffer pH 7.4. Results denote
meanTS.D. from at least 3 batches.
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extent of charged lipid incorporation and head–group interac-
tion. Zeta potential analysis of the DDA and DDA–TDB
formulations show that all liposomes tested have a high net
positive charge (44–52 mV; Table 1), clearly resulting from the
cationic nature of DDA. Neither the method of preparation nor
the inclusion of TDB within the liposome membranes was
shown to make a significant difference to this positive surface
charge, suggesting that no marked electrostatic interactions
between the DDA and TDB lipids occurred at the surface of the
vesicle. In addition, the adsorption of Ag85B–ESAT-6 antigen
(0.01 mg/ml) to both DDA and DDA–TDB liposomes made
no significant difference to the measured size or zeta potential
of vesicles (Table 1), suggesting that at these concentrations
adsorption of antigen on the vesicle surface made no significant
impact on the liposomes physical attributes.
Unfortunately, dispersions of DDA liposomes are physically
unstable and prolonged storage at 4 -C is not possible without
the visible occurrence of aggregation and precipitates. This is
supported by the particle size data shown in Fig. 1A. The
average particle size of pure DDA liposomes increases rapidly
during the first 10 days of storage at 4 -C due to aggregation or
fusion of the liposomes, and after 45 days of storage it is
impossible to determine the size of the liposomes using
dynamic light scattering. In contrast, the liposomes containing
small amounts of the glycolipid TDB showed little or no change
in particle size, indicating that the presence of TDB in the DDA
liposome bilayers leads to short- as well as long-term
stabilization of the size of the liposomes. Similar results were
also shown at room temperature (25 -C; Fig. 1B), with the
particle size of DDA liposomes increasing approximately 4-fold
after only 7 days, compared to DDA–TDB (11 mol%) which
showed no significant increase in size after 14 days. However,
by day 28, both formulations had shown a marked increase in
vesicle size (Fig. 1B). Zeta potential analysis of these
formulations reveals no major changes in the surface character-
istics of liposomes stored at 4 -C for up to 28 days (Fig. 2A),
however storage at room temperature conditions resulted in a
marked reduction in the zeta potential of the DDA and DDA–
TDB liposomes at day 14 and 28, respectively (Fig. 2B).
It has previously been shown that double chain glycolipids,
such as TDB and TDM, inhibit fusion between phospholipidvesicles [30,31]. The stabilizing effect is presumably caused by
the relatively large hydrophilic trehalose head–group increasing
the overall hydration of the liposomal surface, preventing
dehydration of the quaternary ammonium head–groups and
aggregation caused by reduced charge repulsion. Alternatively,
the trehalose moiety might act as a steric barrier that prevent
close contact between opposing liposomes, which is a prereq-
uisite for the formation of aggregation or fusion of the liposomes
[30,31].
3.2. Differential scanning calorimetry (DSC)
Lipid bilayers formed of DDA undergo a main phase
transition at a characteristic temperature (Tm) at which the
liposomal bilayers go from a lower temperature gel-phase do-
minated by ordered alkyl chain conformations to a high-
temperature fluid-phase characterized by disordered alkyl chain
conformations [32]. The phase transition temperature (Tm) is
detected as a peak in the heat capacity curve obtained by DSC.
DSC thermograms for DDA dispersions containing increasing
molar concentrations of the glycolipid TDB are shown in Fig. 3
and the parameters Tm, DHm, and DT2 are summarized in
Table 2.
Table 2
Thermodynamic parameters characterizing the gel to liquid phase transition in
liposomes formed by DDA incorporating 0, 6.4, 11 and 20 mol% TDB
obtained using differential scanning calorimetry at a scan rate of 30 -C/h
Mol% TDB Tm (-C) DHm (kcal/mol) T2 (-C
0 47.20 11.32 0.36
6 45.91 13.45 1.73
11 42.40 (47.4) 15.61 5.74
20 41.80 14.53 0.41
The liposomes were dispersed in 10 mM Tris buffer with pH 7.4.
Fig. 2. Time development of average zeta potential of DDA (–0– ) and DDA/
TDB (11 mol%) (–*–) liposomes dispersed in 10 mM Tris-buffer (pH 7.4) and
stored at (A) 4 -C and (B) 25 -C.
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7.4, is characterized by one sharp well defined endothermic
peak with Tm 47.2 -C and DT2 0.36 -C, characteristic of a
highly cooperative gel-fluid phase transition in good agreement
with DSC results for DDA liposomes reported in the literature
[15,23,25,33,34]. In contrast, for DDA liposomes containing
6.4 mol% TDB a broadening of the gel-fluid phase transition
peak (DT1/2=1.73 -C) was observed, and a shoulder wasFig. 3. Differential scanning heat capacity curves obtained at a scan rate of
30 -C/h for freshly prepared DDA liposomes incorporating 0, 6.4, 11 and 20
mol% TDB. The liposomes were dispersed in 10 mM Tris buffer adjusted to pH
7.4. The second of three DSC heating scans is shown. The curves have been
normalized to molar content. A fall in phase transition temperature from 47.2 to
41.7 -C is observed. Notice that the scans have been displaced on the heat
capacity axis for clarity.)detected at the high temperature side. In addition, introduction
of TDB leads to a shift in Tm toward lower temperatures. The
same kind of complex phase behavior was detected for DDA
liposomes containing 11 mol% TDB. The broad gel-fluid phase
transition revealed two components with an overall maximum
at 42.4 -C, suggesting that more than one cooperative heat
transition occurs, most likely due to changes in the local
structure of the lipid bilayer, resulting in a lateral phase
separation and formation of domains enriched in TDB [35].
This demonstrates that the acyl chains of the TDB glycolipids
are in fact incorporated into the hydrophobic core of the DDA
lipid bilayers causing a change in the lipid chain packing
properties. This thermotropic phase behavior appeared to
depend on the molar ratio of TDB, as the high temperature
component of the heat transition peak practically disappears
with increasing amounts of TDB, as indicated by the DSC
thermograms for the dispersions containing 20 mol% TDB.
Overall, the present DSC results demonstrate that TDB has a
pronounced concentration dependent effect on the thermotropic
phase behavior of DDA liposomes. It should be emphasized
that despite the slight decrease in Tm observed when TDB is
introduced into the bilayer, the liposomes do not break up. In
fact, TDB significantly improves the colloidal stability of DDA
dispersions as indicated by the development in particle size
shown in Fig. 1A.
3.3. Adsorption of antigen
To characterize the antigen adsorption to DDA–TDB
liposomes the mycobacterial Ag85B–ESAT-6 fusion protein
was selected as model antigen. This protein has been identified
as a promising vaccine antigen against tuberculosis in several
studies [8,36,37] a disease for which a Th1 type immune
response is required for protection.
The degree of adsorption of antigen (% of total used; 0.01
mg) to both DDA and DDA–TDB liposomes was determined
using 125I-labelled Ag85B–ESAT-6. The addition of TDB had
no detrimental effect on protein adsorption, with both DDA
and DDA–TDB formulations adsorbing approximately 70–
80% of the total antigen initially added (Table 3). The
adsorption of antigen to the formulation is most probably
electrostatic in nature. The antigen is highly negatively charged
and has a theoretical pI value of 4.80. In contrast, the zeta
potential analysis demonstrates that all DDA–TDB formula-
tions had a high net positive charge of 46 to 52 mM. The
method of preparation was shown to impact on antigen
Table 3
Adsorption of antigen to adjuvant liposomes
Formulation Aqueous heat method Lipid hydration method
DDA 74.3T3.2% 69.9T10.2%
DDA–TDB 78.7T2.1% 67.0T2.8%
125I-labelled Ag85B–ESAT-6 was adsorbed onto DDA or DDA–TDB (11
mol%) liposomes prepared by either the aqueous heat or lipid hydration method
as in Table 1 and non-associated antigen removed by ultracentrifugation. Values
denote meanTS.D. from at least 3 experiments.
Fig. 4. Adsorbed antigen retention over time of DDA (–0– ) and DDA–TDB
(11 mol%) (–*– ) liposomes dispersed in 10 mM Tris buffer (pH 7.4) and
stored at 4 -C (A) and 25 -C (B). 125I-labelled Ag85B–ESAT-6 was adsorbed
to liposomes and antigen retention of Ag85B–ESAT-6 was determined on the
basis of 125I radioactivity recovered in the suspended pellets after ultracentri-
fugation. Results represent percentage retention of initial adsorbed antigen
(Table 3) expressed as meanTS.D., n =3.
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prepared by the lipid hydration method; however, this could
be related to the small vesicle size associated with this method,
which could result in some small vesicle populations failing to
pellet effectively during the centrifugation process.
After removal of non-adsorbed Ag85B–ESAT-6 via centri-
fugation, antigen retention to the liposomes after storage at both
4 -C and 25 -C was measured (Fig. 4). After 7 days storage at
4 -C (Fig. 4A) antigen retention in both formulations dropped to
approximately 80% of the initial antigen adsorption. Subse-
quently at time points thereafter, retention values for DDA–
TDB liposomes remained constant at ¨80% with no further
losses of antigen being measured (Fig. 4A). In contrast, further
loss of antigen was associated with the DDA formulation with
retention values continuing to drop to approximately 65% (of
initial adsorption values) at day 14 and subsequently levelling
around this value thereafter (Fig. 4A). Storage of the formula-
tions at 25 -C had no major impact on antigen retention
compared to refrigerated samples over the period of analysis,
however at this temperature, significant differences (P <0.05,
Student’s t-test) in antigen retention between liposomes with
and without TDB were only apparent at day 28 (Fig. 4B).
3.4. Morphology studies
3.4.1. TEM
Initially, TEM was used to investigate the morphological
characteristics of liposomes prepared by either the aqueous heat
or lipid hydration method. Fig. 5A shows that DDA liposomes
prepared by aqueous heat method are angular and relatively
large in size (>1 Am) with notable signs of vesicle aggregates.
The larger vesicle size of liposomes produced by aqueous heat
compared to lipid hydration is also apparent when comparing
the DDA–TDB (Fig. 5B vs. Fig. 5E) and DDA–TDB/protein
(Fig. 5C vs. Fig. 5F) liposome formulations. The formulation
of the liposomes had less of an impact on the morphological
characteristics of the aqueous heat preparations, with no
notable morphological changes seen upon addition of 11
mol% TDB (Fig. 5B) and protein (Fig. 5C) with vesicles
remaining around 1 Am in size. However, the extent of
aggregation appears reduced when TDB is incorporated within
the liposomal membranes, again suggesting the stabilizing role
TDB may play in the vesicle construct.
In agreement with the particle size analysis, when prepared
by lipid hydration method, DDA liposomes (Fig. 5D) were
smaller (¨500 nm) and less angular than those prepared by
aqueous heat (Fig. 5A), although some large vesicles andaggregates are present. Addition of 11 mol% TDB to the
liposome formulation (Fig. 5E) gave more spherical vesicles
which display less aggregation compared to their DDA
counterparts, possibly again due to the bilayer stabilizing
effect of the longer alkyl chain TDB. Similar to aqueous
heat preparations, no obvious morphological change was
apparent upon addition of protein to lipid hydration
liposomes (Fig. 5F).
3.4.2. Cryo-TEM
The cryo-TEM micrograph shown in Fig. 6 confirms that
liposomes are formed when a lipid film of DDA containing 11
mol% TDB is hydrated in Tris-buffer. The spontaneously
formed DDA liposomes incorporating TDB displayed in Fig. 1
were rather polydisperse in size and shape, nevertheless most
of the liposomes had a ‘‘lens-like’’ shape and diameters below
500 nm. However, as noted in the TEM investigations some
giant vesicles with diameters in the micrometer range were also
observed. As expected from the high content of positively
charged DDA lipids the cryo-TEM micrograph shows that the
vesicles were predominantly unilamellar. This general feature
of bilayer systems containing charged lipids can be explained
by inter-bilayer repulsive electrostatic forces, which prevent
multiple bilayer stacking [38].
Fig. 5. DDA Liposomes in Tris-buffer prepared by aqueous heat method (A) were angular, and relatively large in size, and show significant vesicle aggregation. No
morphological changes are seen upon addition of 11 mol% TDB (B) or protein (C). When prepared by lipid hydration method, DDA liposomes (D) were smaller and
less angular than those prepared by aqueous heat (A), although some large vesicles are present. Addition of 11 mol% TDB to these DDA liposomes gave more
spherical vesicles which display less aggregation (E). Similar to aqueous heat preparations, no obvious morphological change was apparent upon addition of protein
to lipid hydration liposomes (F). In all formulations, liposomes prepared by the aqueous heat method are larger than the lipid hydration counterparts.
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Ag85B–ESAT-6 vaccine
The adjuvant effect of the DDA–TDB formulation was
subsequently tested in mice using the Ag85B–ESAT-6 fusion
protein as a model antigen. Mice were immunized three times
with the vaccine antigen mixed with DDA liposome dispersions
incorporating 0, 6.4, 11 or 20 mol% TDB, respectively. One
week after the third immunization, the specific immune response
of the blood cells was investigated by restimulation with
Ag85B–ESAT-6 in vitro (Fig. 7A) and subsequently measuring
IFN-g and IL-5 as indicators of a Th1 and Th2 response,
respectively. All formulations with TDB were able to induce
high levels of IFN-g, with the formulation containing 11% TDB
giving rise to the highest response (96.2T1.6 ng/ml). Low levels
of IL-5 (below 120 pg/ml) were seen with all formulationscontaining TDB (results not shown). No response was seen after
re-stimulation with irrelevant antigens, i.e., tetanus toxoid or the
merozoite surface protein from malaria (data not shown).
Furthermore, the ability of DDA–TDB to induce antibody
responses after immunization was investigated by immunizing
with Ag85B–ESAT-6 in the various formulations of DDA–
TDB three times and measuring the levels of antigen-specific
antibodies of the IgG1 and IgG2b isotypes by ELISA. The IgG2a
titer which is widely used as an indicator of a Th1-type of
immune response was not evaluated since the gene is deleted in
C57Bl/6 mice [39]. As shown in Fig. 7B, the addition of TDB to
DDA in general causes an elevation of the antibody levels with a
level of IgG2b in the group receiving 11% TDB-DDA 9-fold
higher compared to DDA alone. The groups receiving 11 and
6.4% TDB exhibited the highest ratio of IgG2b compared to
Fig. 6. Cryo-TEM micrograph of DDA vesicles containing 11 mol% TDB
vitrified from 25 -C. The sample exists predominantly as unilamellar vesicle
structures. Morphology and size varies between the vesicles. No bilayer
fragments were observed. Scale bar=200 nm.
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of a Th1-immune response. Increasing the amount of TDB to
20% did not further enhance the immune response but rather had
a negative influence on the levels of antibodies induced.Fig. 7. Induction of immune response using DDA–TDB liposomes as adjuvant. Rele
with 2 Ag of Ag85B–ESAT-6 administered in DDA liposomes incorporating 0, 6.4, 1
after the first immunization and re-stimulated in vitro with the Ag85B–ESAT-6 (5Based on these immunological data as well as the physico-
chemical data on stability of DDA–TDB liposomes it was
decided to use DDA liposomes with 11% TDB as the
standard formulation. In order to evaluate the adjuvant
activity of DDA–TDB compared to an adjuvant already
approved for human use, mice were immunized with
Ag85B–ESAT-6 in either DDA–TDB or Alum and the
immune responses post-immunization evaluated. As shown in
Fig. 8A, immunization with DDA/TDB leads to high levels of
IFN-g release and low levels of IL-5 whereas Alum-
immunized mice exhibited the opposite pattern with a
neglible IFN-g secretion and higher levels of IL-5. DDA/
TDB give rise to the same high levels of IgG1 antibody titers
as seen after immunization with alum whereas the level of
Ig2b antibodies were 8-fold higher after immunization with
DDA–TDB compared to alum, indicating a dominant Th1-
type of immune response obtained with DDA–TDB (Fig.
8B). To further evaluate the lymphocyte subset mediating the
observed immune response, spleen cultures from immunized
mice were blocked with monoclonal antibodies against the
CD8 and CD4 receptors before restimulating with Ag85B–
ESAT-6. Adding anti-CD4 to the cultures decreased the
immune response considerably whereas minor effect was
seen after blocking of the CD8 receptor (Fig. 9). The IFN-gase of IFN-g from blood lymphocytes isolated from C57Bl/6j mice immunized
1 or 20 mol% TDB, respectively (A). Blood lymphocytes were isolated 5 weeks
g/ml). IgG1 and IgG2b Ag85B–ESAT-6-specific antibody dilution curves (B).
Fig. 8. Immune responses generated by DDA–TDB liposomes and alum. Release of IFN- and IL-5 from blood lymphocytes isolated from C57Bl/6j mice immunized
with 2 Ag of Ag85B–ESAT-6 administered in DDA–TDB with 11 mol% TDB incorporated or alum (A). IgG1 and IgG2b Ag85B–ESAT-6-specific antibody
dilution curves (B).
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flow cytometry analysis with intracellular staining of IFN-g
(results not shown).Fig. 9. Release of IFN-g from spleen lymphocytes isolated from C57Bl/6
mice immunized with 2 Ag of Ag85B–ESAT-6 emulsified in DDA/TDB.
Splenocytes were isolated 1 week after the final immunization and blocked
with anti-CD4 or anti-CD8 prior to re-stimulation with 5 Ag/ml of
Ag85B–ESAT-6.The adjuvant liposomes presented here shows the com-
mendable ability to stimulate both a cell mediated Th1 immune
response and an antibody response. This broad stimulation of
the immune response is a unique property of DDA–TDB and
makes the adjuvant advantageous for a high number of disease
targets including infectious diseases and cancers. The testing of
DDA–TDB as an adjuvant for vaccines with different
requirements is presently ongoing and would provide important
information on the applicability of the adjuvant. Besides
potentiating the immune response of DDA, incorporation of
TDB was shown to effectively stabilize the DDA liposomes.
This is, to our knowledge, the first time it has been
demonstrated that cationic adjuvant liposomes are stabilized
by incorporating synthetic glycolipid analogues of TDM into
the liposome bilayers, thus overcoming the major obstacle for
using DDA as an efficient adjuvant system, while simulta-
neously improving the immunogenicity of the adjuvant
considerably.
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